AeroVironment (AVAV) Q1 2027 earnings review
A Tale of Two Segments: Autonomous Systems Soars While SCDE Stalls
AeroVironment opened FY27 with record Q1 revenue of $480.5M, but the headline 6% YoY growth masks a stark internal divergence. The Autonomous Systems (AxS) segment is accelerating rapidly, growing 21% YoY fueled by a 71% surge in Uncrewed Aircraft Systems. Conversely, the Space, Cyber and Directed Energy (SCDE) segment—primarily the legacy BlueHalo business—is reversing hard, contracting 21% YoY and generating an $8.9M Adjusted EBITDA loss. Despite the SCDE drag, a massive bookings quarter ($0.7B) pushed funded backlog to an all-time high of $1.5B, allowing management to reaffirm full-year guidance with 86% revenue visibility.
🐂 Bull Case
A book-to-bill ratio of 1.4 in Q1 drove funded backlog to a record $1.5B (up 37% YoY). This cash-certain pipeline practically guarantees the company's baseline revenue targets for the fiscal year.
Uncrewed Aircraft Systems revenue accelerated an incredible 71% YoY to $120M, driven by massive new awards like the $117M P550 contract for the Army's Long-Range Reconnaissance program.
🐻 Bear Case
The SCDE segment is not just shrinking (revenue down 21% YoY); its profitability has collapsed. Adjusted EBITDA flipped from a $3.8M profit a year ago to an $8.9M loss this quarter.
With FY27 CapEx guided at a staggering 12-14% of revenue to fund manufacturing and facility expansions, free cash flow generation will remain heavily suppressed in the near term.
⚖️ Verdict: ⚪
Neutral/Stable. The core Autonomous Systems portfolio is a premier defense asset generating spectacular volume. However, the SCDE segment looks broken following the FY26 SCAR contract loss, and its deteriorating margins prevent AVAV from realizing its full earnings potential.
Key Themes
Uncrewed Aircraft Systems (UAS) Accelerating
The AxS segment's 21% YoY growth was entirely carried by its Uncrewed Aircraft Systems division, which posted an accelerating 71% YoY revenue spike ($120M vs $70M). The recent $117M U.S. Army order for the P550 Long-Range Reconnaissance (LRR) program cements AVAV's hardware dominance in the tactical edge.
SCDE Segment Reversing Hard
Management's narrative of 'landmark strategic wins' is directly contradicted by the financials of the Space, Cyber and Directed Energy (SCDE) segment. Revenue is decelerating dramatically, falling 21% YoY to $134.5M. The decline was broad-based: Space & Directed Energy fell 28% YoY, and Cyber & Mission Solutions fell 16% YoY. This indicates a severe hangover from the loss of the SCAR program in Q3 FY26.
Record Bookings Defy Baseline Expectations
AVAV secured $0.7 billion in bookings in Q1 alone, equating to a 1.4x book-to-bill ratio. Key multi-year IDIQs and specific task orders, including a $51M Army order for Switchblade 600, are converting to funded backlog at a stable, highly visible rate. Funded backlog now sits at an all-time high of $1.5 billion, up 37% YoY.
Gross Margins Weighed Down By Intangibles
While GAAP gross margin mathematically improved YoY (26% vs 21%), it remains structurally depressed by heavy non-cash purchase accounting expenses. Q1 bore $43.4 million of intangible amortization and purchase accounting, punishing GAAP metrics and obscuring underlying operational leverage. Adjusted Service Gross Margin also compressed to a concerning 8% from 13% YoY.
LOCUST Laser Commercialization Achieves Milestone
AVAV's directed energy portfolio captured a crucial proof point: a $52M initial international commercial order for the LOCUST laser weapon system. This validates management's prior thesis that commercializing BlueHalo's bespoke technologies would unlock exportability and international scale.
Geopolitical Demand Pulls Forward Global Adoption
The macro backdrop of global conflicts continues to function as a forcing function for AVAV's entire portfolio. Beyond U.S. DoD adoption, the company highlighted a $30M award to provide Puma Systems for Germany's LARUS program, proving that European restocking remains a durable, multi-year tailwind.
Capital Expenditures Decelerating Free Cash Flow
AVAV maintained its FY27 guidance for CapEx at 12% to 14% of revenue. At the midpoint of revenue guidance ($2.175B), this implies ~$280M in cash outlays for manufacturing capacity (including the Salt Lake City expansion), integration, and cloud implementations. This elevated spend will severely throttle near-term free cash flow yield.
Other KPIs
Accelerating. Up 18% YoY from $52.8M in Q1 FY26. This segment is single-handedly keeping AVAV's profitability afloat, compensating for the deep losses occurring in the SCDE segment.
Stable but elevated. Increased sequentially from $570.4 million in Q4 FY26. Management has historically struggled to rein in this working capital drag, particularly stemming from the service-heavy nature of the BlueHalo acquisition.
Decelerating. Down from $377.3 million at the end of FY26 (April 30, 2026). The sequential burn was driven by $108.2M used in investing activities, notably heavy property and equipment acquisitions ($44M) and net purchases of investments.
Guidance
Stable. The midpoint implies roughly 10% YoY growth against FY26's $1.97B. Management expects a 45/55 split between H1 and H2, indicating an acceleration in delivery cadences in the back half of the fiscal year.
Stable. The implied ~14% margin at the midpoint is perfectly consistent with FY26 actuals, meaning management is not forecasting any aggregate margin expansion this year. Crucially, they expect 2/3 of this EBITDA to be generated in H2, representing significant execution risk late in the year.
Decelerating. The midpoint of $3.18 represents a slight contraction from the $3.31 delivered in FY26. Management notes this includes increased depreciation resulting from planned facility and capacity expansion.
Key Questions
SCDE Profitability Trough
With the SCDE segment posting an $8.9M Adjusted EBITDA loss in Q1 and shrinking 21% YoY, when do you expect this segment to trough, and what is the specific bridge back to positive margins?
H2 Execution Risk
Guidance implies that 66% of the year's Adjusted EBITDA must be delivered in the second half of FY27. What gives you confidence in this steep hockey-stick ramp, and is it primarily dependent on AxS volume or a turnaround in SCDE?
SCAR Commercialization Update
Following the termination of the SCAR contract last year, you noted plans to commercialize the BADGER technology. Is any revenue from this commercialization effort baked into the H2 FY27 guidance?
Working Capital Normalization
Unbilled receivables climbed another $67M sequentially to $637M. Is this the structural peak for unbilled receivables, and when will we see meaningful working capital conversion to free cash flow?